| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/NEN.0B013E3181A52A7F |
| P698 | PubMed publication ID | 19458546 |
| P50 | author | Claude-Alain Maurage | Q66360626 |
| P2093 | author name string | Philippe Lassalle | |
| Marc Baroncini | |||
| Stéphane Sarrazin | |||
| Serge Blond | |||
| Estelle Adam | |||
| Maryse Delehedde | |||
| Jean-Francois Minéo | |||
| Manuelle Debunne | |||
| Rose-Mary Siminski | |||
| P2860 | cites work | Systematic variation in gene expression patterns in human cancer cell lines | Q28145747 |
| P433 | issue | 6 | |
| P304 | page(s) | 633-641 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Journal of Neuropathology & Experimental Neurology | Q15716771 |
| P1476 | title | Endocan expression and localization in human glioblastomas | |
| P478 | volume | 68 |
| Q36704453 | A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion |
| Q57291279 | Adipocyte proteome and secretome influence inflammatory and hormone pathways in glioma |
| Q38211375 | Aggressive pituitary adenomas--diagnosis and emerging treatments |
| Q87381708 | Biological and clinical implications of endocan in gastric cancer |
| Q35500737 | Characteristics of serum endocan levels in infection |
| Q49722319 | Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma. |
| Q53246001 | Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas. |
| Q42283730 | ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells |
| Q37688603 | ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma |
| Q28069363 | Endocan and the respiratory system: a review |
| Q61796690 | Endocan as a marker of microvascular inflammation in kidney transplant recipients |
| Q45226937 | Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors |
| Q37341628 | Endocan immunoreactivity in the mouse brain: method for identifying nonfunctional blood vessels. |
| Q39431959 | Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan |
| Q48150410 | Endocan is markedly overexpressed in severe erectile dysfunction |
| Q38745168 | Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression |
| Q47139612 | Endocan silencing induces programmed cell death in hepatocarcinoma |
| Q46843616 | Endocan, a new invasion and angiogenesis marker of pituitary adenomas. |
| Q58113472 | Endocan, sepsis, pneumonia, and acute respiratory distress syndrome |
| Q35681482 | Endocan: A new marker for cancer and a target for cancer therapy |
| Q38265707 | Endocan: a new molecule playing a role in the development of hypertension and chronic kidney disease? |
| Q38299725 | Endocan: a novel circulating proteoglycan |
| Q92909603 | Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma |
| Q48649719 | Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. |
| Q36240767 | Endurance training significantly increases serum endocan but not osteoprotegerin levels: a prospective observational study |
| Q64078200 | Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels |
| Q47380167 | Evaluation of the associations between endothelial dysfunction, inflammation and coagulation in Crimean-Congo hemorrhagic fever patients. |
| Q37162853 | Expressions of Endocan in Patients with Meningiomas and Gliomas |
| Q37046635 | HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas |
| Q38754716 | Human cytomegalovirus infection contributes to glioma disease progression via upregulating endocan expression |
| Q84797546 | Identification of endothelial cell‐specific molecule‐1 as a potential serum marker for colorectal cancer |
| Q39523688 | Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin |
| Q33739749 | Leucine-rich glioma inactivated 3: integrative analyses support its prognostic role in glioma |
| Q38207964 | Markers for sepsis diagnosis in the forensic setting: state of the art. |
| Q47148074 | Overexpression of Endothelial Cell-Specific Molecule 1 Correlates with Gleason Score and Expression of Androgen Receptor in Prostate Carcinoma. |
| Q47105893 | Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression |
| Q45415175 | Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease |
| Q28075990 | Prognostic value of endocan expression in cancers: evidence from meta-analysis |
| Q37657319 | Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. |
| Q37724813 | Serum endocan levels before and after surgery on low-grade gliomas |
| Q88253973 | Serum endocan levels in patients with cardiac syndrome X |
| Q59812312 | Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality |
| Q28391635 | The future role of personalized medicine in the treatment of glioblastoma multiforme |
| Q35550081 | The non glycanated endocan polypeptide slows tumor growth by inducing stromal inflammatory reaction. |
| Q35067738 | Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma. |
| Q91024552 | WITHDRAWN: ESM1-dependent mesenchymal transition enhances radioresistance of glioblastoma via transcriptional regulation of NFκB |
Search more.